Stock price performance of Anthera Pharmaceuticals, Inc. is analyzed for various periods using several stock trading signals. The stock price have dropped -68.26% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -80.23% . Looking at the past 52 week period, the stock price is down -76.82% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Anthera Pharmaceuticals, Inc. has a negative value of -82.07 compared to overall market performance. Company shares have received an average consensus rating of Hold for the current week The stock has recorded a 20-day Moving Average of 17.67% and the 50-Day Moving Average is 60.37%.The 200 Day SMA reached 80.37%
Anthera Pharmaceuticals, Inc. is having a Relative Strength Index of 40.34 which indicates the stock is not yet over sold or over bought based on the technical indicators. Stocks of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rallied by 15.81% during the past week but lost 9.17% on a 4-week basis. The company has outperformed the S&P 500 by 15.68% in the past week but underperformed the index by 9.98% in the last 4 weeks.
Company has reported several Insider transactions to the SEC, on Nov 18, 2015, Colin Hislop (Chief Medical Officer) sold 12,500 shares at 5.31 per share price.On Oct 13, 2015, Debra Odink (Chief Technology Officer) sold 1,205 shares at 6.15 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Anthera Pharmaceuticals Inc was Reiterated by Piper Jaffray on Dec 29, 2016 to Overweight, Lowers Price Target to $ 1.35 from a previous price target of $7 .Anthera Pharmaceuticals Inc was Reiterated by H.C. Wainwright on Dec 29, 2016 to Buy, Lowers Price Target to $ 3 from a previous price target of $10 .Anthera Pharmaceuticals Inc was Downgraded by Citigroup to Neutral on Dec 29, 2016. Anthera Pharmaceuticals Inc was Downgraded by Jefferies to Hold on Dec 29, 2016.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) : On Friday heightened volatility was witnessed in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) which led to swings in the share price. The stock opened for trading at $0.5988 and hit $0.65 on the upside , eventually ending the session at $0.6189, with a gain of 6.34% or 0.0369 points. The heightened volatility saw the trading volume jump to 2,031,605 shares. The 52-week high of the share price is $4.9 and the company has a market cap of $26 million. The 52-week low of the share price is at $0.51 .
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Companys clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjogrens Syndrome, Graves Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.